| Today’s Big NewsNov 18, 2024 |
| By Angus Liu CSL Behring is shutting down its U.S. R&D hub for cell and gene therapy in Pasadena, California, Fierce Biotech has learned. |
|
|
|
By Gabrielle Masson Novartis is adding another radiopharmaceutical program to its collection, penning a deal worth $745 million in biobucks for rights to a cancer candidate from Ratio Therapeutics. |
By Andrea Park Despite lingering barriers to equity, women continue to do incredible, groundbreaking work throughout pharma, biotech and medtech. As seen in the following profiles of 10 of the fiercest women in life sciences, they’re spearheading Big Pharma business development, guiding up-and-coming biotechs and leading clinical research into potentially lifesaving technologies and therapeutics. |
Sponsored by Adaptive Biotechnologies Discover how minimal residual disease (MRD) assessment is accelerating multiple myeloma drug development through FDA's latest guidance. |
|
Explore the latest additions to the GS®️ expression toolbox and strategies for using these technologies to drive successful development of your molecule from discovery through to commercial supply. During this webinar, you’ll also hear about innovative methods for creating the next generation of cell expression systems.
|
|
By Nick Paul Taylor Neurogene has dropped plans to keep studying the high dose of its Rett syndrome gene therapy because of an adverse event that has left a patient in critical condition. The discontinuation has pushed back the anticipated completion of enrollment in the low-dose cohort. |
By Nick Paul Taylor Disease markers stabilized or improved in cardiomyopathy patients who received a single dose of Intellia Therapeutics’ in vivo CRISPR therapy in a phase 1 trial. But the incumbents look set to fight to hold on to the market, with Alnylam Pharmaceuticals sharing early-phase data on its next-generation prospect. |
By James Waldron A spinout from the University of Edinburgh in Scotland is armed with 15 million pounds ($19 million) in seed funding as the newly unveiled biotech continues its mission to find one-time cancer treatments. |
By Fraiser Kansteiner Eisai has terminated a phase 3 study of lorcaserin as a potential adjunct treatment for patients with Dravet syndrome, a rare form of epilepsy that starts in infancy. The company is also shutting down an extended access program in which patients were able to access the medication off-label. |
By Darren Incorvaia French biotech Innate Pharma is recruiting natural-born killers to target B cell non-Hodgkin lymphoma. The company’s tetraspecific antibody controlled tumors and improved survival in mice and reduced cancerous B cells in cynomolgus macaques. |
By Eric Sagonowsky The scope of Gilead Sciences' recent round of layoffs is coming into clearer view with the revelation that the company is planning more than 100 cuts at its corporate headquarters. |
By Noah Tong Civil liberty organizations are sounding the alarm on a bill lawmakers are trying to push through during the lame duck session. They say it will give any presidential administration unchecked power to devastate nonprofit groups that are not ideologically aligned. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," we explore a neuroscientist's alleged misconduct and its impact on the future of neurodegenerative disease research. |
|
|---|
|
|
|
The future of gene therapy is here, but with it comes manufacturing constraints, supply chain issues, and regulatory questions. Join us on November 20 for the Fierce Cell and Gene Virtual Event. Register Now!
|
|
| WhitepaperExplore the robust cross-platform agreement between scRNA-seq and bulk RNA-seq, ensuring consistent and reproducible data on immune cell presence. Sponsored by: IQVIA Laboratories |
| WhitepaperThe use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
| WhitepaperThis e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development. Sponsored by: Blue Matter |
| WhitepaperUnlock the secrets to faster, cost-effective biologics production with intensified biomanufacturing – download the whitepaper and power up your bioprocessing game! Sponsored by: Syngene International Ltd. |
| WhitepaperLearn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes. Presented by: Thermo Fisher Scientific |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
